# Evidence Report: TP53

**Entity Type**: Feature
**Entity ID**: `TP53`

## Metadata

- **Feature Type**: gene

## Summary

1. High-level context  
- Disease context: Amyotrophic lateral sclerosis (ALS)  
- Model system context: Internal datasets from Amprenta, likely patient-derived or mixed biological samples (not explicitly specified as in vitro or in vivo)  
- Matrix context: Not explicitly stated; datasets are transcriptomics and proteomics data, presumably from relevant tissue or biofluids for ALS  

2. Per-omics findings:  
- Lipidomics: No data available for TP53 in lipidomics.  
- Metabolomics: No data available for TP53 in metabolomics.  
- Proteomics: TP53 protein is detected in two internal proteomics datasets (test_proteomics_mixed and test_proteomics_canonical), indicating presence at the protein level in ALS-related samples. No quantitative differential expression values reported.  
- Transcriptomics: TP53 shows consistent upregulation across multiple transcriptomics datasets with log2 fold changes ranging from +0.90 to +2.50 and significant p-values (e.g., log2FC=1.20, p=0.001; log2FC=2.50, p=0.010), indicating increased gene expression in ALS contexts.  

3. Cross-omics convergence:  
- TP53 is consistently upregulated at the transcript level and detected at the protein level in ALS-related samples, suggesting concordant transcriptional and proteomic evidence for increased TP53 activity or abundance.  
- No metabolite or lipid features related to TP53 were reported, so convergence is limited to transcriptomics and proteomics.  

4. Cross-omics divergence:  
- Lack of metabolomics and lipidomics data for TP53 limits assessment of divergence.  
- Proteomics data lack quantitative fold change or statistical significance details, so the extent of protein-level regulation relative to transcriptomics is unclear.  

5. Disease, model system, and matrix context (detailed):  
- The data derive from internal Amprenta datasets focused on ALS, a neurodegenerative disease.  
- The samples are described as "mixed" or "canonical," suggesting a combination of sample types or conditions, but exact model systems (e.g., patient tissue, cell lines) and matrices are not specified.  
- Transcriptomics and proteomics data indicate TP53 upregulation in ALS-related biological contexts.  

6. Key open questions and next experimental steps:  
- Quantify TP53 protein expression changes with statistical rigor to confirm proteomic upregulation in ALS.  
- Determine the specific sample types and biological matrices to contextualize TP53 changes.  
- Investigate downstream pathways and functional consequences of TP53 upregulation in ALS models.  
- Explore metabolomics and lipidomics to identify potential metabolic or lipid alterations linked to TP53 activity.  
- Validate findings in independent ALS cohorts and relevant in vivo or in vitro models.